AZNAstraZenecaSigning up patients
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Metastatic Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 60 (planned)
- Started
- Mar 12, 2024
- Main results expected
- Nov 24, 2026
- Fully finished
- Nov 24, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs).
Measured over: Through study completion, an average of 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06267729 · record last updated 2026-02-23 · checked 2026-11-09 15:47 UTC